Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Affymax Inc. stock logo
AFFY
Affymax
$0.00
$0.00
$0.00
$0.00
N/A7.342,186 shsN/A
AOBI
American Oriental Bioengineering
$0.00
$0.00
$0.00
$0.00
N/A7.285 shsN/A
AOLS
Aeolus Pharmaceuticals
$0.00
$0.00
$0.01
N/A1.2835 shsN/A
AOXG
Aoxing Pharmaceutical
$0.01
$0.01
$0.00
$0.02
$2.86M6.735,649 shsN/A
BOPH
Bohai Pharmaceuticals Group
$0.00
$0.00
$0.00
$0.00
$20K1.7830,425 shs50,000 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Affymax Inc. stock logo
AFFY
Affymax
0.00%0.00%+700.00%-66.67%+14.29%
AOBI
American Oriental Bioengineering
0.00%0.00%0.00%0.00%0.00%
AOLS
Aeolus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
AOXG
Aoxing Pharmaceutical
0.00%0.00%0.00%-6.25%+5.63%
BOPH
Bohai Pharmaceuticals Group
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/AN/AN/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
AOXG
Aoxing Pharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
BOPH
Bohai Pharmaceuticals Group
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Affymax Inc. stock logo
AFFY
Affymax
0.00
N/AN/AN/A
AOBI
American Oriental Bioengineering
0.00
N/AN/AN/A
AOLS
Aeolus Pharmaceuticals
0.00
N/AN/AN/A
AOXG
Aoxing Pharmaceutical
0.00
N/AN/AN/A
BOPH
Bohai Pharmaceuticals Group
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/AN/AN/AN/A
AOXG
Aoxing Pharmaceutical
N/AN/AN/AN/AN/AN/A
BOPH
Bohai Pharmaceuticals Group
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Affymax Inc. stock logo
AFFY
Affymax
N/AN/A0.00N/AN/AN/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/A0.00N/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
AOXG
Aoxing Pharmaceutical
N/AN/A0.00N/AN/AN/AN/AN/A
BOPH
Bohai Pharmaceuticals Group
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/AN/AN/A
AOXG
Aoxing Pharmaceutical
N/AN/AN/AN/AN/A
BOPH
Bohai Pharmaceuticals Group
N/AN/AN/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Affymax Inc. stock logo
AFFY
Affymax
4N/AN/ANot Optionable
AOBI
American Oriental Bioengineering
3,720N/AN/ANot Optionable
AOLS
Aeolus Pharmaceuticals
4N/AN/ANot Optionable
AOXG
Aoxing Pharmaceutical
350381.21 million313.35 millionNot Optionable
BOPH
Bohai Pharmaceuticals Group
N/A19.52 millionN/ANot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Affymax stock logo

Affymax OTCMKTS:AFFY

$0.0008 0.00 (0.00%)
As of 07/3/2025

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

American Oriental Bioengineering OTCMKTS:AOBI

$0.0005 0.00 (0.00%)
As of 07/3/2025

American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting. It also offers over-the-counter pharmaceutical products comprising Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS) and other PMS and menopause-related symptoms; and Boke Nasal Spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis. In addition, the company provides various nutraceutical products, such as soybean peptide based drinks, tablets, powder, and instant coffee. Further, it is involved in the wholesale and retail of pharmaceutical and nutraceutical products. The company sells its products directly and through distributors to hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical stores, and other retail outlets in the People's Republic of China. American Oriental Bioengineering, Inc. is headquartered in Beijing, China.

Aeolus Pharmaceuticals OTCMKTS:AOLS

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Aoxing Pharmaceutical OTCMKTS:AOXG

$0.0075 0.00 (0.00%)
As of 07/3/2025

Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.

Bohai Pharmaceuticals Group OTCMKTS:BOPH

$0.0010 0.00 (0.00%)
As of 03/11/2019

Bohai Pharmaceuticals Group, Inc. engages in the production, manufacture, and distribution of herbal pharmaceuticals based on traditional Chinese medicine. Its products include lung nourishing syrup, tongbi capsules, tongbi tablets, zhuangyuanshenhailong medicinal wine, bazhenyimu cream, fangfengtongsheng granule, and zhengxintai capsules. The company was founded on January 9, 2008 and is headquartered in Yantai, China.